Nanodropper, Inc. v. J4J, LLC: Voluntary Dismissal in Ophthalmic Drug Delivery Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Nanodropper, Inc. v. J4J, LLC |
| Numéro de dossier | 0:24-cv-01475 (D. Minn.) |
| Tribunal | Tribunal fédéral de première instance du district du Minnesota |
| Durée | Apr 2024 – Jul 2024 94 Days |
| Résultat | Retrait volontaire de la plainte (retrait par le demandeur) |
| Brevets en cause | |
| Produits incriminés | J4J, LLC’s PRECISION DROPPER |
Aperçu du dossier
Les parties
⚖️ Demandeur
Minnesota-based medical device company focused on reducing eyedrop waste and improving dosing precision with its NANODROPPER® device.
🛡️ Défendeur
Company associated with the competing PRECISION DROPPER product in the ophthalmic drug delivery market.
Brevets en cause
This case involved **U.S. Patent No. 10,695,216 B2**, covering technology in the ophthalmic drug delivery device space — specifically, innovations related to precision eyedrop dispensing that reduce drop volume and improve dosing consistency. Patent holders in this space typically assert claims covering device geometry, fluid mechanics, or adapter mechanisms designed to interface with standard eyedrop bottles.
- • US 10,695,216 B2 — Precision eyedrop dispensing technology
Vous concevez un dispositif médical similaire ?
Check if your ophthalmic device design might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The case terminated via a Notice of Voluntary Dismissal, filed by Nanodropper, Inc. as plaintiff on July 25, 2024. No damages were awarded, no injunctive relief was granted, and no court ruling on the merits of infringement or patent validity was issued. Specific terms underlying the decision to dismiss — whether a confidential settlement, licensing agreement, or strategic withdrawal — are not disclosed in publicly available case records.
Principales questions juridiques
The verdict cause is classified as an Infringement Action, meaning Nanodropper initiated this proceeding to enforce its patent rights under 35 U.S.C. § 271 against J4J, LLC’s PRECISION DROPPER. The voluntary dismissal, however, means no judicial findings regarding literal infringement, the doctrine of equivalents, or patent validity were produced.
Voluntary dismissals in patent cases of this duration typically reflect one of several strategic dynamics: pre-litigation settlement or licensing, plaintiff’s reassessment of claim strength, defendant’s design-around, or a commercial resolution outside court. Without court-issued claim construction orders or summary judgment rulings, the legal record from this case does not establish precedent regarding the scope or validity of U.S. Patent No. 10,695,216 B2.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in the ophthalmic drug delivery device market. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir tous les brevets liés à ce domaine technologique
- See which companies are most active in ophthalmic device patents
- Understand claim construction patterns for precision droppers
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Precision eyedrop dispensers
1 Brevet en cause
In ophthalmic drug delivery space
Options de contournement
Disponible pour la plupart des réclamations
✅ Points clés à retenir
Voluntary dismissal within 94 days reflects early-stage resolution dynamics common in single-patent, direct-competitor disputes.
Rechercher la jurisprudence connexe →No precedential claim construction issued — U.S. Patent No. 10,695,216 B2 scope remains judicially untested.
Explorer les précédents →Rule 41 dismissal terms (with or without prejudice) are critical to assess for potential refiling risk.
Understand dismissal rules →Nanodropper’s enforcement posture confirms active patent monetization strategy in the ophthalmic device space.
Monitor Nanodropper’s portfolio →Licensing conversations may be the practical resolution pathway in this technology category.
Découvrez les tendances en matière de licences →Foire aux questions
The case involved U.S. Patent No. 10,695,216 B2 (Application No. US16/255,152), covering ophthalmic drug delivery device technology related to Nanodropper’s precision eyedrop dispensing products.
The specific basis for voluntary dismissal was not publicly disclosed. Common reasons include confidential settlement, licensing resolution, design-around by the defendant, or plaintiff’s strategic reassessment of claim strength after early case development.
While no precedential ruling was issued, the case signals active enforcement of precision dropper patents. Competitors and new market entrants in the ophthalmic adapter space should prioritize FTO clearance against Nanodropper’s IP portfolio.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- U.S. Patent No. 10,695,216 B2 — USPTO/Google Patents
- Case Docket No. 0:24-cv-01475 — PACER Federal Court Records
- U.S. District Court for the District of Minnesota — Patent Litigation Procedures
- Cornell Legal Information Institute — 35 U.S.C. § 271
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.